POP-OUT | CLOSE

An Information Portal to 105339 Biological Macromolecular Structures

 
4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE
 
STI is found in 16 entries
STI
  •   Chemical Component Summary   Hide
    Name 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE
    Identifiers 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide
    4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
    Synonyms STI-571;IMATINIB
    Formula C29 H31 N7 O
    Molecular Weight 493.60 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key KTUFNOKKBVMGRW-UHFFFAOYSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00619   (Stereoisomeric match)
    Name Imatinib
    Groups approved
    Description Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
    Synonyms
    • 4-(4-METHYL-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
    • alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-P-toluidide
    • Imatinib
    • Imatinib Methansulfonate
    • Imatinibum
    • STI 571
    [more]
    Salts Imatinib Mesylate
    Brand names
    • Celonib
    • Enliven
    • Gleevec
    • Glivec
    • Imatib
    • Mesylonib
    • Mitinab
    • Plivatinib
    • Shantinib
    [more]
    Affected organism Humans and other mammals
    Indication For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
    Pharmacology Imatinib is an antineoplastic agent used to treat chronic myelogenous leukemia. Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of Abl with Bcr (breakpoint cluster region), termed Bcr-Abl. As this is now a continuously active tyrosine kinase, Imatinib is used to decrease Bcr-Abl activity.
    Mechanism of action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML). It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib also inhibits the receptor tyrosine kinases for platelet derived growth factor (PDGF) and stem cell factor (SCF) - called c-kit. Imatinib was identified in the late 1990s by Dr Brian J. Druker. Its development is an excellent example of rational drug design. Soon after identification of the bcr-abl target, the search for an inhibitor began. Chemists used a high-throughput screen of chemical libraries to identify the molecule 2-phenylaminopyrimidine. This lead compound was then tested and modified by the introduction of methyl and benzamide groups to give it enhanced binding properties, resulting in imatinib.
    Route of administration Oral
    Categories
    • Antineoplastic Agents
    • Protein Kinase Inhibitors
    ATC-Code L01XE01
    AHFS-Code
    • 10:00.00
    • 92:00.00
    CAS number 152459-95-5
    Targets
    Name Sequence search Pharmacological action Actions
    Tyrosine-protein kinase ABL1   Search  unknown inhibitor
    Platelet-derived growth factor receptor beta   Search  unknown antagonist
    Mast/stem cell growth factor receptor Kit   Search  yes antagonist#multitarget
    Platelet-derived growth factor receptor alpha   Search  unknown antagonist
    Macrophage colony-stimulating factor 1 receptor   Search  unknown antagonist
    [more]
     
Ligand Image